We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+15.33%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
+$15.1M
Cap. Flow
-$14.8M
Cap. Flow %
-5.28%
Top 10 Hldgs %
70.61%
Holding
30
New
4
Increased
13
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$18.2M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$14M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M
4
SLN
Silence Therapeutics
SLN
+$8.95M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.93M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$21.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$19.1M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.8M
4
KALV
KalVista Pharmaceuticals
KALV
+$7.19M
5
FOLD
Amicus Therapeutics
FOLD
+$7.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$29.9M 10.69%
200,285
+87,061
+77% +$11.8M
IRON icon
2
Disc Medicine
IRON
$2.84B
$25.1M 8.98%
511,041
+7,952
+2% +$373K
PCVX icon
3
Vaxcyte
PCVX
$8.01B
$23.4M 8.37%
204,987
-10,693
-5% -$964K
CGON icon
4
CG Oncology
CGON
$6.19B
$19.6M 7.01%
+520,119
New +$18.2M
COGT icon
5
Cogent Biosciences
COGT
$6.54B
$18.5M 6.61%
1,712,899
+38,980
+2% +$380K
CRGX
6
DELISTED
CARGO Therapeutics
CRGX
$18.5M 6.61%
1,002,461
+145,612
+17% +$2.6M
CYTK icon
7
Cytokinetics
CYTK
$10.7B
$17.5M 6.25%
331,283
+59,247
+22% +$3.3M
PHAT icon
8
Phathom Pharmaceuticals
PHAT
$849M
$15.8M 5.65%
874,590
+281,284
+47% +$3.93M
MLTX icon
9
MoonLake Immunotherapeutics
MLTX
$1.59B
$15.1M 5.39%
+298,974
New +$14M
CELC icon
10
Celcuity
CELC
$4.29B
$14.1M 5.04%
946,335
+185,394
+24% +$3.06M
ARGX icon
11
argenx
ARGX
$52.9B
$12M 4.28%
22,111
-42,085
-66% -$21.3M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.98B
$9.66M 3.45%
501,978
+82,324
+20% +$1.7M
SLN
13
Silence Therapeutics
SLN
$495M
$8.75M 3.13%
+481,127
New +$8.95M
ABVX
14
Abivax
ABVX
$11.5B
$7.47M 2.67%
648,019
+20,259
+3% +$243K
INZY
15
DELISTED
Inozyme Pharma
INZY
$7.16M 2.56%
1,368,810
+228,500
+20% +$1.19M
MRUS
16
DELISTED
Merus
MRUS
$6.56M 2.34%
131,240
-33,533
-20% -$1.75M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$6.44M 2.3%
556,489
-571,989
-51% -$7.19M
NMRA icon
18
Neumora Therapeutics
NMRA
$302M
$5.72M 2.04%
432,996
+42,912
+11% +$501K
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$8.88B
$5.6M 2%
109,567
-370,114
-77% -$19.1M
IRWD icon
20
Ironwood Pharmaceuticals
IRWD
$634M
$4.62M 1.65%
1,120,409
+6,585
+0.6% +$35.4K
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$11.4B
$2.63M 0.94%
37,432
-141,157
-79% -$11.8M
ITOS
22
DELISTED
iTeos Therapeutics
ITOS
$2M 0.71%
195,704
-171,725
-47% -$2.62M
CTNM
23
Contineum Therapeutics
CTNM
$506M
$1.48M 0.53%
77,297
+4,466
+6% +$85.6K
AVBP icon
24
ArriVent BioPharma
AVBP
$1.31B
$1.11M 0.4%
+47,266
New +$1.07M
LBPH
25
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.05M 0.38%
31,529
-39,913
-56% -$1.37M
1
2

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
FWM
FFT Wealth Management Philadelphia, Pennsylvania $552M AUM 16.82% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return

Saturn V Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Saturn V Capital Management held 30 positions worth $280M, up 5.7% from $265M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Saturn V Capital Management withdrew a net $14.8M in Q3 2024, closing 5 positions and reducing 8 holdings. Its most notable exit was Amicus Therapeutics, an estimated $7.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in CG Oncology worth $19.6M.

  • Saturn V Capital Management's largest Q3 2024 buy was CG Oncology: 520,119 shares worth $19.6M.
  • Saturn V Capital Management added most to Ascendis Pharma A/S in Q3 2024, an estimated $11.8M increase.
  • Saturn V Capital Management's biggest Q3 2024 reduction was argenx, cutting an estimated $21.3M.
  • Saturn V Capital Management fully exited Amicus Therapeutics in Q3 2024, selling an estimated $7.08M.
  • Saturn V Capital Management's ten largest holdings make up 71% of its $280M portfolio in Q3 2024.
  • Saturn V Capital Management opened 4 new positions and closed 5 in Q3 2024.
  • Saturn V Capital Management's portfolio value rose 5.7% quarter-over-quarter to $280M.

Based on Saturn V Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.